{"schema_version":"secwatch.filing_event.v1","accession":"0001628280-23-011672","form_type":"8-K","ticker":"CPIX","cik":"0001087294","company_name":"CUMBERLAND PHARMACEUTICALS INC","filed_at":"2023-04-17T23:59:59+00:00","discovered_at":"2026-05-14T18:03:37.900283+00:00","generated_at":"2026-06-17T01:13:39.384920+00:00","sec_items":["8.01"],"event_type":"regulatory","sentiment":"positive","materiality_score":0.6,"calibrated_materiality_score":0.6,"confidence":"high","headline":"Cumberland Pharma's Caldolor expected to qualify for separate Medicare reimbursement under NOPAIN Act from 2025","bullets":["NOPAIN Act requires Medicare to provide separate reimbursement for non-opioid pain management products in outpatient hospital and ambulatory surgical center settings.","Caldolor (ibuprofen injection) is a non-opioid analgesic indicated for pain management, shown to reduce opioid use.","Reimbursement applies to products furnished between Jan 1, 2025 and Jan 1, 2028; CMS to issue regs in 2024.","Caldolor is FDA approved for mild to severe pain in adults and pediatric patients age 6 months+.","Company expects this will positively impact Caldolor's Medicare reimbursement."],"urls":{"canonical":"https://secwatch.observer/filing/0001628280-23-011672","json":"https://secwatch.observer/filing/0001628280-23-011672.json","markdown":"https://secwatch.observer/filing/0001628280-23-011672.md","text":"https://secwatch.observer/filing/0001628280-23-011672.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023011672/0001628280-23-011672-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/1087294/000162828023011672/cpix-20230414.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-06-17T01:13:39.384920+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}